Press Release

Protein Discovery Adds Directory of Mass Spectrometry to Scientific Staff. Jeremy Norris Ph.D. Will Oversee Tissue Imaging and Profiling Service.

Knoxville, Tennessee, November 16, 2005—Protein Discovery, Inc., a privately held life sciences company, today announced that Jeremy Norris, Ph.D., an imaging mass spectrometry expert, has joined the company as director of mass spectrometry. Dr. Norris will be responsible for the company’s tissue imaging and profiling mass spectrometry service.

Prior to joining Protein Discovery, Dr. Norris was an adjunct instructor of biochemistry at Vanderbilt University, where he also received his doctor of philosophy degree in Chemistry under the guidance of Professor Richard M. Caprioli. While at Vanderbilt University, Dr. Norris was responsible for all internal operations related to the University’s tissue imaging work for outside companies and shared responsibility for designing and implementing the University’s Serum Proteomics Core. Dr. Norris has produced dozens of presentations, book chapters, patents, and publications related to imaging mass spectrometry and proteomics in general.

“It has been my privilege to be closely involved in the development and advancement of imaging mass spectrometry and its diagnostic and prognostic potential,” said Dr. Norris. “The director of mass spectrometry position at Protein Discovery will enable me to take this exciting technology to the next level—commercial deployment into diverse research and clinical settings.”

Protein Discovery, Inc. has retained exclusive worldwide licenses from Vanderbilt University to provide commercial imaging mass spectrometry services and to develop associated sample preparation products. Protein Discovery has also retained rights from the University of Texas to perform the imaging services. This intellectual property portfolio provides the company with the exclusive rights to provide imaging mass spectrometry services for preclinical purposes.

About Protein Discovery
Protein Discovery, Inc. is a privately held life sciences company developing solutions for molecular research, drug discovery and development, and medical diagnostics using high throughput mass spectrometry. The company’s imaging mass spectrometry (IMS) service allows pharmaceutical and biotech customers to gain important insights into disease progression and metabolic response. The company is also developing a powerful suite of sample preparation products specifically designed to meet the data quality and throughput demands of customers using mass spectrometry in the life sciences industry. The ability to reproducibly identify and quantify suites of clinically significant biomarkers with spatial resolution will enhance patient health by improving the diagnosis, prognosis, and treatment of disease. For additional information, please visit www.proteindiscovery.com.

TOP